About the Company
biovie inc. (otc pink: bivi) is developing novel drug therapies for life-threatening complications of chronic liver disease. our initial target is ascites, which can occur in patients with advanced cirrhosis due to hepatitis, nash (non-alcoholic steatohepatitis), or alcoholism. ascites affects about 100,000 americans and carries an estimated 40% mortality rate within two years of being diagnosed. the company’s new drug candidate biv201 is about to enter a phase 2 clinical trial in the us. it’s based on a drug (terlipressin) not yet available in the us, but approved in about 40 countries for treating related complications of liver cirrhosis. the fda has never approved a drug to treat ascites and there is a significant unmet medical need for our novel therapy, which has orphan drug status. biovie has attracted funding from strategic investors including aspire capital, cuong do, the global strategy lead for samsung, and hari kumar, founder of adheron therapeutics which he sold to roche fo
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $BIVI News
BioVie (BIVI) Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial - Hagens Berman
Faces Securities Fraud Class Action After Uncovering Potential Scientific Misconduct In Failed Phase 3 Clinical Trial - Hagens Berman ...
Lost Money on BioVie Inc.(BIVI)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / March 16, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a ...
Levi & Korsinsky Notifies BioVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - BIVI
THE LAWSUIT: A class action securities lawsuit was filed against BioVie Inc. that seeks to recover losses of shareholders who were adversely affected by alleged securities fraud between August 5, 2021 ...
Bears are Losing Control Over BioVie Inc. (BIVI), Here's Why It's a 'Buy' Now
BioVie Inc. (BIVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among ...
Shareholders that lost money on BioVie Inc.(BIVI) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
NEW YORK, NY / ACCESSWIRE / March 15, 2024 / If you suffered a loss on your BioVie Inc. (NASDAQ:BIVI) investment and want to learn about a ...
BioVie Inc (NASDAQ: BIVI)’s Loss Of -8.37% Profited Investors
BioVie Inc (NASDAQ:BIVI) traded at $0.65 at close of the session on Monday, March 18, made a downward move of -8.37% on its previous day’s price. Looking at the stock we see that its previous close ...
BIVI Apr 2024 3.000 put
BioVie Inc. (BIVI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among ...
AD/PD 2024: BioVie’s novel NE3107 shows promise but confirmatory trial needed
However, a significant limitation of the early data is that the majority of trial participants were excluded from the analysis following GCP violations at multiple trial sites.
Loading the latest forecasts...